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Abstract
Background: Distorted activity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the most robustly
documented biological abnormalities in major depression. Lithium is central to the treatment of affective disorders, but little
is known about its effects on the HPA system of depressed subjects.
Objective: To assess the effects of lithium monotherapy on the HPA system of patients with major depression by means of
the combined DEX/CRH test.
Method: Thirty drug-naive outpatients with major depression (single episode or unipolar recurrent; SCID I- and II-confirmed)
were treated with lithium monotherapy for four weeks. The DEX/CRH test was conducted directly before intake of the first
lithium tablet and four weeks thereafter. Weekly ratings with the HDRS21 were used to determine response ($50%
symptom reduction) and remission (HDRS #7).
Results: Lithium levels within the therapeutic range were achieved rapidly. Tolerability was good; no patient terminated the
treatment prematurely. Response and remission rates were 50% and 33% respectively. Compared to the DEX/CRH test
before the start of the treatment, a considerable and significant increase in all CRH-stimulated ACTH and cortisol parameters
could be detected in the second DEX/CRH test. When analysed with particular regard to responders and non-responders,
that significant increase was only present in the responders.
Conclusions: We were able to demonstrate that lithium leads to a significant activation of the HPA system. This is possibly
connected to stimulation of hypothalamic arginine vasoporessin (AVP), to direct intracellular effects of lithium on pituitary
cells and to an induction of gene expression.
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Introduction
Depression is a frequent and severe medical problem. One of
the cornerstones of treatment is antidepressant medication [1,2].
However, a challenging issue in the pharmacotherapy of
depression remains the high rate of non-response to antidepres-
sants [3]. Therefore, a major aim of research is to develop
alternative drugs with alternative modes of action.
A system repeatedly studied as a target for new antidepressive
drugs is the hypothalamic-pituitary-adrenocortical (HPA) system
[4,5,6]. It has been postulated that depression (or at least a
subgroup of depression) is associated with overactivity of the HPA
system, possibly due to impaired negative feedback control [7].
Most antidepressants are supposed to partly act by improving the
negative feedback control [8]. Other substances reducing the
overload or improving the negative feedback have been tested for
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27613the treatment of depression, however with ambiguous results
[9,10].
Another fundamental drug used to treat affective disorders with
an alternative mode of action is lithium. Lithium induces multiple
intracellular modifications, which are yet not fully understood
[11,12,13]. Beside its widespread use in the prophylactic treatment
of bipolar [14,15,16] and unipolar affective disorder [1,2,17],
lithium in the form of lithium augmentation is a major strategy for
treating (unipolar) depression not responding to antidepressant
monotherapy [18,19].
Not established, though demonstrated effective in several older
studies, is lithium monotherapy for the treatment of acute
depression. At least seven studies from the 1970s and 1980s
[20,21,22,23,24,25,26] showed that lithium monotherapy is as
effective as a tricyclic antidepressant and the two of those studies
that included a placebo component [21,23] demonstrated
superiority over the placebo (overview: [27]). Several of these
older studies have methodological shortcomings (e. g. small sample
size) [27]. To our knowledge, in the last 20 years lithium
monotherapy for acute unipolar depression has not been the
subject of systematic research.
The impact of lithium on the HPA system has repeatedly been
investigated mainly in pre-clinical studies. Older cell culture and
animal studies [28,29,30,31,32,33,34] showed an enhancing effect
of lithium on the release of CRH, AVP, ACHT, and cortisol, and
on the glucocorticoid receptor (GR) messenger RNA. With regard
to humans, certain older studies with methodological limitations
showed an increase of plasma cortisol in affectively ill patients after
initiation of lithium therapy [35,36], whilst other did not [37].
After long-term lithium treatment, the findings have tended to
show a decrease in plasma cortisol levels [38].
In a previous study, we investigated a group of unipolar
depressed patients (N=30) who did not respond to a treatment
with an antidepressant and who were subsequently treated with
lithium augmentation [39,40]. We conducted the most sensitive
challenge test of the HPA system, the combined dexamethasone/
CRH test (DEX/CRH test) [8,41], right before, and two to four
weeks during, lithium augmentation. Interestingly, patients had a
significantly higher ACTH and cortisol response to CRH
stimulation in the DEX/CRH test during lithium augmentation
compared to the values at baseline, regardless of response to the
lithium augmentation [39,42].
Because it couldn’t be concluded from the results of this
preceding study whether the increase in HPA system activity was
due to a direct pharmacological effect of the lithium ion or
whether it was instead an effect of the complex lithium
augmentation mechanism (i. e. pre-treatment with an antidepres-
sant, followed by a lithium/antidepressant combination), we here
present the results of a study with 30 unipolar, acutely depressed,
drug-naive subjects who were treated with lithium monotherapy.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
This study was conducted at the Department of Psychiatry,
Technical University of Dresden between January 2003 and
February 2004. Patients who contacted the outpatient clinic of the
department on their own, were transferred to the outpatient clinic
by other physicians, or who followed a call for study participation
in the local newspapers could be included into the study. Except
for one patient, who was transferred to the inpatient ward because
of the severity of the symptoms, all participants were outpatients.
The study protocol was approved by the local ethical committee
and the study has been carried out in accordance with the
Declaration of Helsinki. After complete description of the study to
the subjects, written informed consent was obtained. The
laboratory ACTH and cortisol measurements and the statistical
analyses were performed at the Max-Planck Institute of Psychiatry,
Munich.
Inclusion criteria
Patients of both genders, aged 18 to 75 years, with a major
depressive episode, single episode or recurrent (DSM IV criteria)
were included into the study. Diagnoses were confirmed by the
Structured Clinical Interview for DSM IV (SCID I; German
version) [43,44,45]. On the day of study, included participants had
to have a score of at least 15 on the Hamilton Depression Rating
Scale, 21-item version (HDRS21) [46]. Due to the inclusion criteria
participants had to have been free of psychotropic drugs for at
least 14 days (fluoxetine: 35 days) with the exception of
benzodiazepines (max. 20 mg diazepam or equivalent per day).
However, we were able to include only subjects who have not been
treated pharmacologically for the index episode (only drug-naı ¨ve
patients).
Exclusion criteria
The exclusion criteria were (SCID I): a history of a manic or
hypomanic episode (bipolar disorder), current alcohol abuse or
dependency, organic brain disease, schizophrenia or schizoaffec-
tive disorder. Further exclusion criteria were: current intake of
psychotropic drugs (see above); acute or chronic somatic
conditions that might contraindicate lithium or that might
influence the regulation of mineralo- or glucocorticoids; pregnancy
or lactation. Personality disorders were not an exclusion criterion
but were systematically recorded by conducting a SCID II
interview with each subject.
Lithium treatment
Patients started lithium treatment on the evening of the first
combined DEX/CRH test (baseline). Lithium was administered at
a daily dose of two times 12.2 mEq lithium carbonate (26450 mg).
Standardized 12-hour serum lithium levels were measured at day
3, 7, 14, 21, and 28 of lithium treatment. The lithium dose was
adapted individually to achieve a serum level within the
established therapeutic range [47] between 0.5 and 1.0 mEq/L.
Psychopathological ratings, response and remission
criteria
The HDRS21, the Clinical Global Impressions Scale (CGI) [48]
and the Beck Depression Inventory (BDI) [49] used as a self-rating
scale were conducted at weekly intervals (on day 0, 7, 14, 21, 28)
by trained and experienced raters (TB, DR, or UL). In accordance
with established criteria [50,51], patients were classified as
responders if their HDRS21-score showed a decrease of 50% or
more in the course of the four-week-study and remission was
defined as a HDRS21-score of 7 or less on day 28. Response or
remission had to be confirmed after one week by the same criteria.
In line with most studies on antidepressive drugs we decided to use
the HDRS21 to define response and remission, because it is a rater
based scale (in contrast to the BDI) and it is much more
sophisticated as compared to the one-item CGI.
The Dexamethasone/CRH test
The combined DEX/CRH test was performed in accordance
with the established research procedure [6,41,52,53,54]: The
Lithium Treatment of Depression and DEX/CRH Test
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dexamethasone at 11 p.m. The next day, blood was drawn at 3
p.m., 3.30 p.m., 3.45 p.m., 4 p.m., 4.15 p.m., and 4.30 p.m.
through an intravenous catheter (through the wall technique).
100 mg of human CRH was administered intravenously at 3 p.m.
shortly after the first blood collection. All blood samples were
collected in pre-frozen, EDTA- and aprotinin (Trasylol
TM)-
containing tubes and immediately centrifuged in a centrifuge
cooled to 4uC. The plasma was frozen directly after separation
from the blood cells and stored at 280uC.
The plasma cortisol and ACTH concentrations in the first
specimen (baseline), collected at 3 p.m., reflect the suppressive
effects of the dexamethasone administered the day before, whereas
the other five plasma cortisol and ACTH concentrations reflect
the additional effects of the CRH stimulation. Peak levels, CRH
response values (Delta) and area under the curve (AUC) values of
the cortisol and ACTH in the six consecutive blood samples were
used as indicators of the response to the combined DEX/CRH
test. The Delta values were obtained by subtracting the 3 p.m.
hormone values (before CRH injection) from the individual peak
value. The AUC values were defined as the natural logarithms of
the trapezoidal integration of the six cortisol and ACTH
concentrations. Missing values (about 1%) were estimated by the
individual values of the previous and subsequent sample.
Laboratory analysis
All probes were analysed together in one assay at the end of the
entire study. In order to determine the plasma cortisol concen-
tration, a commercially available radioimmunoassay (RIA) kit
(ICN Biomedicals, Carson, CA) was used. The detection limit was
0.3 ng/ml plasma; intra- and interassay coefficients of variation
for 20 and 40 ng/ml were ,7%. For plasma ACTH measure-
ments, an immunoradiometric assay without extraction (Nichols
Institute, San Juan Capistrano, CA) was used providing a
detection limit of 4.0 pg/ml. The intra- and interassay coefficients
of variation at 20 pg/ml plasma were ,8%.
Sample size calculation
The study was designed according to the above mentioned
previous results from our group [39]. According to these findings,
we expected an effectsize d(z) (=Cohen’s d for dependent
measures) of 0.65 for observing an increased cortisol response
(AUC) to a second DEX/CRH test after four weeks of lithium
treatment. From this effect size, we calculated an optimal sample
size of n=29 under standard assumptions (alpha error=0.05;
power=0.9) using G*Power 3.1 [55].
Statistical Analysis
Changes between the initial clinical or endocrine variables at
baseline and at follow-up were evaluated with Wilcoxon’s matched
pairs test. Differences between responders and non-responders
were assessed with Fisher’s exact test and the Mann-Whitney U
test. Differences were regarded as significant when p,0.05. All
analyses were performed with SPSS, Version 17.0. The sample
size estimation was performed with G*Power 3.1 [55].
Results
Study population
Forty patients were screened for participation and 30 were able
to be included in the study (Figure 1). Reasons for non-inclusion
were: no diagnosis of depression (N=2), significant somatic
comorbidity (N=2), refusal to participate (N=2), and non-
appearance at the first study visit (N=3). One patient refused
lithium treatment after having accepted the baseline DEX/CRH
test. She was excluded from the study. The remaining 30 patients
(15 men, 15 women) completed four weeks of lithium treatment
but one patient (male) refused the second DEX/CRH test. The
HDRS21 score was 21.764.7 (mean 6 SD, range: 15–33) at study
entry. For details on demographic and clinical data see Table 1.
Figure 1. CONSORT 2010 Flow Diagram.
doi:10.1371/journal.pone.0027613.g001
Table 1. Demographic and clinical data of the study
population (N=30) (mean 6 standard deviation).
Age (years) 45.97610.93
Gender (male:female) 15:15
Age at onset of mood disorder (years) 36.83610.24
Duration of index episode (months) 17.03616.26
Number of previous depressive episodes 1.7761.78
diagnosis: single episode (DSM-IV: 296.2) : recurrent episodes
(DSM-IV: 296.3)
9:21
doi:10.1371/journal.pone.0027613.t001
Lithium Treatment of Depression and DEX/CRH Test
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Lithium serum levels and lithium doses are presented in Table 2.
Lithium tolerability was good. Side effects were recorded weekly.
The majority of patients actually showed signs of probablyside-effects
of lithium (70% of the patients at day 28), however such side-effects
were generally mild. No patient terminated the lithium treatment
prematurely. The side-effects observed were those that are typically
expected under lithium treatment (in order of appearance: polyuria,
ataxia, increased thirst, diarrhoea, and tremor).
According to the criteria mentioned above, fifteen of the 30
patients (8 women, 7 men) responded within 4 weeks after
initiation of lithium treatment (in mean after 2.3361.18 weeks).
Ten of these 15 responders even showed remission. There was no
significant difference between responders and non-responders with
regard to age, gender, baseline severity of depression, lithium doses
or lithium serum level (data not shown). The HDRS21, BDI and
CGIseverity scores (mean 6 SD) on day 0 were 21.764.70,
24.068.1, and 5.760.7 respectively, and declined to 11.165.1,
15.069.1, and 4.661.2 on day 28 (p,0.001 for all three changes;
Wilcoxon’s matched pairs test).
Endocrinological results
Full group. At day 0 (before start of lithium treatment), the
ACTH peak was 25.37627.19 pg/ml and the cortisol peak was
83.77681.49 ng/ml (for baseline, AUC, and delta values, and
cortisol/ACTH ratios cf. Table 3). After four weeks of lithium
treatment (day 28) ACTH at baseline (before CRH injection) was
comparable to day 0, but both all CRH-stimulated ACTH
parameters and all cortisol parameters were significantly higher
during lithium treatment compared to pre-treatment (ACTH peak
28.48624.65 pg/ml, p=0.048; cortisol peak 104.84678.95 ng/
ml, p=0.012; cf. Table 3).
Responder and non-responder. With regard to response or
non-response to the lithium treatment, differences could be
detected between responders and non-responders. Before the
start of the treatment (day 0), patients who responded in the
following four weeks to the lithium medication displayed
numerically lower values on all ACTH and cortisol parameters
than subsequent non-responders. However, only the difference for
baseline ACTH (before CRH injection) was significant
(14.1661.85 vs. 18.64610.27 pg/ml, p=0.049, Mann-Whitney
U test, cf. Table 4).
After four weeks of lithium treatment (day 28) a substantial rise
in the ACTH and cortisol parameters (significant for all
parameters except baseline ACTH) was observed only in
responders to the lithium treatment, while the non-responders
showed a (non-significant) decrease for most of the parameters of
the DEX/CRH test (cf. Figure 2). After this adjustment
(responders started with lower pre-treatment values but exhibited
an increase, while non-responders started with higher pre-
treatment values but tended to develop a decrease), no relevant
differences in the DEX/CRH test results could be found between
responders and non-responders at day 28.
Discussion
This is, to our knowledge, the first systematic study of lithium
monotherapy in treating acute unipolar depression in more than
20 years. Lithium serum levels can be considered as adequate and
well-tailored, reaching the therapeutic range after just one week,
with a low degree of variance. The response (50%) and remission
(33%) rates have to be called moderate, but match the efficacy
typically seen in clinical studies on antidepressive compounds. In a
recent analysis including 182 RCTs of antidepressants, the pooled
response rate was 53.8% [56]. However, this study was not
designed to test the efficacy of lithium monotherapy. Because
neuroendocrinology was the field of enquiry, no control group was
included. Lithium tolerability was good, despite mean lithium
serum levels of .0.8 mEq/L at week 3 and 4.
Table 2. Lithium serum levels and lithium doses (N=30).
lithium carbonate doses Lithium serum level (mEq/L)
mean ± SD Range mean ± SD range
day 3, mEq/d 24.460 – 0.4660.11 0.26–0.69
mg/d 90060–
day 7, mEq/d 26.8464.96 18.3–36.6 0.5660.14 0.26–0.88
mg/d 9906183 675–1350
day 14, mEq/d 33.5566.94 18.3–48.8 0.7160.19 0.45–1.31
mg/d 12386256 675–1800
day 21, mEq/d 35.9968.68 18.3–48.8 0.8160.18* 0.51–1.38*
mg/d 13276320 675–1800
day 28, mEq/d 35.9969.21 18.3–48.8 0.8260.19 0.45–1.39
mg/d 13276340 675–1800
*the data from two patients are missing.
doi:10.1371/journal.pone.0027613.t002
Table 3. Endocrinological results of the combined dexamethasone/CRH test before and after four weeks of lithium monotherapy
in 30 unipolar depressed patients (mean, SD).
pre-treatment
(day 0) (N=30)
after 4 weeks of lithium
(day 28) (N=29)
p
Wilcoxon’s matched pairs test
ACTH (pg/ml) baseline (before CRH injection) 16.4067.60 16.2566.47 0.991
ACTH peak 25.37627.19 28.48624.65 0.048
ACTH AUC 1829.361488.9 1978.5961129.47 0.033
ACTH delta 8.97626.20 12.23619.74 0.008
Cortisol (ng/ml) baseline (before CRH injection) 17.28613.40 28.34635.99 0.002
Cortisol peak (ng/ml) 83.77681.49 104.84678.95 0.012
Cortisol AUC 4933.664640.2 5927.7664323.2 0.013
Cortisol delta 66.48673.51 76.5652.46 0.045
doi:10.1371/journal.pone.0027613.t003
Lithium Treatment of Depression and DEX/CRH Test
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clear activation compared to the first DEX/CRH test directly
before the start of lithium (p,0.05 for all ACTH and cortisol
parameters after CRH stimulation). This is in line with previous
results from pre-clinical studies and our study on lithium
augmentation. Previous studies in cell cultures and in animals
[28,30,31,32] as well as in depressed subjects [35,36] showed a
stimulating effect of lithium on CRH, ACTH and cortisol. In
addition, in a cross-sectional study with unipolar and bipolar
patients in different mood states, Watson and colleagues found a
significantly more pronounced cortisol response in the combined
DEX/CRH test when comparing patients taking lithium with
those not taking lithium [57]. However, ours is the first study
demonstrating the HPA-activating effect of lithium monotherapy
in unipolar depressed patients with the DEX/CRH test and a
prospective design.
In an earlier study with the DEX/CRH test, our group found
that lithium augmentation had a clear HPA-system-activating
effect in unipolar depressed patients who did not respond to
preceding monotherapy with an antidepressant [39,40,42]. Due to
the study design it was not clear if the endocrinological changes
observed were a direct effect of the lithium ion or if they required
preceding treatment with an antidepressant. It is well known that
most antidepressants lead to deactivation of the HPA system
[7,8,58]. Given this fact, one explanation for the rise of the CRH-
stimulated parameters in the DEX/CRH test during lithium
augmentation could be that lithium augmentation only restores
the endocrinological situation before the start of the antidepres-
sant. Another explanation could be that the lithium’s enhancing
effect on the HPA system requires neurobiological changes made
by preceding antidepressant treatment, e. g. a sensitisation of post-
synaptic serotonin receptors [59,60].
However, with the results of the presented study it becomes
likely that it is a direct effect of lithium that activates the HPA
system in such way that it becomes more responsive to CRH and
ACTH and probably to external (stress) stimuli as well. A probable
explanation of this finding is related to the osmotic effect of lithium
salts. It is well known that lithium treatment affects renal tubular
function and can lead to polyuria [61,62]. As a compensatory
function, synthesis and secretion of arginine vasopressin (AVP)
from the paraventricular nuclei of the hypothalamus is stimulated.
This was shown in rodents [63], whilst Watson et al. [57] reported
consistent plasma AVP increases in lithium-treated patients with
bipolar disorder or chronic depression. Previously, it has been
shown that continuous infusion with vasopressin in healthy
subjects stimulates the HPA axis and leads to increased ACTH
and cortisol responses to the combined DEX/CRH test [64].
The hypothetical functional connection between elevated AVP
and hyper-responsiveness of the HPA axis is further supported by
animal studies. Male Wistar rats selectively bred for high innate
anxiety are characterized by elevated ACTH and corticosterone
responses to an adaptation of the combined DEX/CRH test, and
treatment with an antagonist against the vasopressin receptor 1
normalized the HPA axis hyperactivity in these animals [65].
Several other findings support central AVP overexpression in these
animals [66], which is caused by a genetic variation in the
promoter region of the AVP gene [67].
In addition, the activating effect of lithium on the HPA system
might be mediated by direct intracellular effects of lithium on
pituitary cells [31,32] and by the induction of gene expression [68].
Interestingly, when viewed separately with regard to responders
and non-responders in the present study, the significant rise in the
post-CRH ACTH and cortisol parameters under lithium treat-
ment is only present in those who responded to the therapy. Most
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and SSRIs [76,77,78] seem to lead to a blunting of the HPA
system response. Predominantly this is interpreted as a normal-
isation of the pathologically-activated HPA system in depressed
subjects and seen as a possible way in which antidepressants
exhibit their clinical effects [9,41,52,79,80]. However, as results in
recent years have shown, the situation has become even more
complex [9,10,58,81]. In the case of lithium treatment, the
stimulation of the HPA axis at least does not hinder its
antidepressive effects.
In addition, the influence of psychotropic drugs on the HPA
system seems to be time-dependent: the inhibiting effect of some
antidepressants on the ACTH and cortisol release seems to need a
number of weeks of treatment, whereas the acute effects tend to
result in stimulation of the hormone release, at least in healthy
volunteers [8]. In contrast mirtazapine acutely inhibits HPA
system activity [82,83]. Lithium augmentation, as stated above,
activates the HPA system, especially in responders [39,42]. The
results of the study presented here suggest that the interpretation of
HPA axis markers in the case of lithium treatment is different due
to its stimulating effects on AVP, which do not exist for
antidepressant drugs. There is a rising awareness of a rather
complex interaction between affective disorders, antidepressive
drugs and the HPA system [8]. A better understanding of the
molecular basis is needed to give a starting point for the
development of new drug therapies with a new mode of action [9].
The study presented here has methodological strengths and
shortcomings. One key strong point is the fact that the study
participants were all drug-naive. Although the initial inclusion
criteria required a drug free period of only two weeks, we were
able to include only subjects without pharmacological pre-
treatment for the depressive index episode. This excludes the
influence of any preceding pharmacotherapy on the clinical or
endocrinological results. The drop-out rate was extremely low (no
patients dropped out, and only one patient declined the second
DEX/CRH test). Diagnoses and depressive symptoms were
monitored and validated using established standardised clinical
interviews and rating scales. With regard to the neuroendocrino-
logical evaluation, however complex, the best-established and
validated test – the combined DEX/CRH test – was used. Lithium
therapy can be considered as optimal provided that lithium serum
levels are very frequently monitored and that lithium levels are
rapidly achieved within the therapeutic range (0.5 to 1.0 mEq/L)
despite a good tolerability.
As the most important limitation, one could mention the lack of
a control group. However, in keeping with most studies with the
DEX/CRH test, our study concentrated on comparing endocri-
nological parameters before the start of the treatment (right before
Figure 2. ACTH and cortisol response in the combined DEX/CRH test on the day before lithium monotherapy (blue line) and after
four weeks of lithium treatment (pink line) in responders and non-responders (n=29).
doi:10.1371/journal.pone.0027613.g002
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after the start of treatment. Since no other systematic changes took
place except the commencement of the lithium therapy, it is rather
unlikely that the changes found in the HPA system might be due to
factors other than the lithium therapy and the possible therapeutic
effects induced by it. However, it cannot be excluded that other
aspects such as the passage of time (4 weeks) or placebo effects
might have had an impact on the endocrinological results. The
absence of a control group means that the clinical efficacy of the
lithium monotherapy found in our study cannot reliably be
interpreted. However, this was not the objective of the study.
In conclusion, this is the first study on lithium monotherapy for
acute unipolar depression in more than 20 years, and the first
prospective study of lithium monotherapy to ever use the DEX/
CRH test. Given the results of the study presented here, of our
preceding study with the DEX/CRH test on lithium augmenta-
tion, of previous studies of the HPA status in depressed or healthy
subjects and the results of the pre-clinical studies in animals and
cell cultures, it can now be regarded as having been established
that lithium has a stimulating effect on the human HPA system.
This is presumably mainly due to an activation of central AVP.
The pronounced effects found in our study confirm the
fundamental significance of the HPA system to the pathophysi-
ology and the treatment of depressive disorders. Developing
fundamentally new treatment approaches continues to be a
challenge, given the fact that some approaches directly targeting
the HPA system have failed in recent years [9,10] and given that
we are still rather far away from understanding the complex
molecular mechanism underlying the regulation of the glucocor-
ticoids in humans.
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